Greater London

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Liver and biliary tract cancer2 trials
• Ovarian cancer2 trials
• Chronic lymphocytic leukaemia1 trial
• Gastric and oesophageal cancer1 trial
• Prostate cancer1 trial
• Thyroid cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 38 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Recruiting6 trials
• Active, not recruiting3 trials
• Completed1 trial

Lead sponsor

• AstraZeneca8 trials
• Acerta Pharma BV1 trial
• Sanofi1 trial

Running trials

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· AstraZeneca· Source

• Recruiting

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· Phase 3· AstraZeneca· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· Phase 3· AstraZeneca· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  NCT06692738· Phase 3· AstraZeneca· Source

• Recruiting

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

  NCT02734004· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  NCT02477696· Phase 3· Acerta Pharma BV· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer2 recruiting
• Lung cancer2 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

  NCT01496313· Phase 4· Sanofi· Source